JP Morgan Notebook Day One: Pfizer/Allergan, Celgene, Gilead, Teva And More
This article was originally published in Scrip
Executive Summary
Pfizer Inc. chairman and CEO Ian Read and Allergan PLC president and CEO Brent Saunders noted in a Jan. 11 interview with Scrip during the 34th Annual JP Morgan Healthcare Conference in San Francisco that investors' biggest concern about the pending $160bn merger of the two companies do not revolve around whether or not the combined entity will continue early-stage research and development or whether more dealmaking is on the horizon.
You may also be interested in...
Roivant's Ramaswamy Woos Celgene's Fouse To Lead Dermavant
The former Celgene president has joined Roivant subsidiary Dermavant with big ambitions to turn the start up into a dermatology leader. Ramaswamy and Fouse talk about next steps for the start up.
Huma Secures EU MDR Approval For Medtech Software That Can Be Used In Any Disease
Huma Therapeutics has secured the first ever EU regulatory approval for a “disease agnostic” class IIb medtech software platform. CEO Dan Vahdat tells Medtech Insight how the product can be configured to monitor patients with any condition.
Moderna CEO Hearing Highlights Dissatisfaction With Patient Assistance Programs
There was bipartisan agreement that Moderna need to ensure that its patient assistance program will be easily accessible for under- and uninsured patients once the US switches to a commercial market for COVID vaccines – a sign of broader frustration with industry copay support initiatives.